Leah Amir
St. Louis, MO (USA)
Role(s):
C-Level Executive (CEO, CFO, etc.)
XCellCure
Find More Startups
Startup
Location:
St. Louis
Industry:
Bio-Technology
Year Founded:
2010
Number Employees:
1-10 people
Business Stage:
Growth (not profitable)
Entity Type:
Limited Liability Company
Description:
XCellCure aims to commercialize a first-to-market, low cost, portable device -AMiAwareTM -able to provide immediate clinical information about a person’s risk for an impending heart attack. Immediate, accurate, information when and where it is needed brings actionable information to patients and physicians allowing them to promptly save lives. Our portable device detects novel markers present in the blood of patients experiencing uncertain discomfort and have a negative electrocardiogram (ECG). The new test alerts them to their probability of having a fatal heart attack over the next 48 hours, and up to 6 months. Conversely, if the novel prognostic markers are negative and the traditional markers are negative, then the patients have the highest assurance they are not having or will experience a heart attack due to their current condition.
Company Advantage executive team with success commercializing new medical products for startup and large companies, enriched with provider-side hospital leadership. Our scientific and medical advisory boards provide critical insight on product development and customer utility. Drawing on technology licensed from leading Universities, XCellCure targets critical unmet needs in the field of cardiology, tissue regeneration and POC technology.
With significant demand in the U.S. Europe and rest of the world we anticipate revenue in excess of $100 MLN in the 4th year of product launch making this an attractive investment.